Original Article
Copyright
©2012 Baishideng Publishing Group Co. , Limited. All rights reserved.
World J Gastroenterol. Feb 28, 2012; 18(8): 746-753
Published online Feb 28, 2012. doi: 10.3748/wjg.v18.i8.746
Table 1 Fibrosis tests composed of laboratory parameters
Fibrosis test Calculation AAR AST/ALT APRI [(AST/ULN)/platelet count (109 /L)] × 100 FibroQ (10 × age × AST × PT INR)/(PLT × ALT) CDS Platelet count (109 /L): > 340 = 0; 280-339 = 1; 220-279 = 2; 160-219 = 3; 100-159 = 4; 40-99 = 5; < 40 = 6 ALT/AST ratio: > 1.7 = 0; 1.2-1.7 = 1; 0.6-1.19 = 2; < 0.6 = 3 API INR: < 1.1 = 0; 1.1-1.4 = 1; > 1.4 = 2 CDS is the sum of the above (possible value, 0-11) Age (yr): < 30 = 0; 30-39 = 1; 40-49 = 2; 50-59= 3; 60-69 = 4; > 70 = 5 Platelet count (109 /L): ≥ 225 = 0; 200-224 = 1; 175-199 = 2; 150-174 = 3; 125-149 = 4; ≤ 125 = 5 API is the sum of the above (possible value, 0-10) Pohl score Positive: AAR ≥ 1 and platelet count < 150 × 109 /L FIB-4 index [Age (yr) × AST (U/L)]/[platelet count (109 /L) × ALT (U/L) 1/2] Lok’s model Log odds (predicting cirrhosis) = -5.56 to 0.0089 × platelet (× 103 /mm3 ) + 1.26 × AST/ALT ratio + 5.27 × PT INR Predicted probability = exp (log odds)/[1 + exp (log odds)]
Table 2 Clinical characteristics of 237 patients with chronic hepatitis C
Male/female 135/102 Age (yr) 54.3 ± 11.6 (19-76) AST (U/L) 101.2 ± 56.0 (21-348) ALT (U/L) 156.3 ± 92.5 (24-637) PT INR 1.049 ± 0.080 (0.88-1.34) PLT (× 103 /μL) 170.9 ± 55.1 (60-373) Hemoglobin (g/L) 14.4 ± 1.37 (9.0-18.0) WBC count (x 109 /L) 5.85 ± 1.73 (2.8-16.7) Creatinine (mg/dL) 0.94 ± 0.23 (1.0-2.0) FT4 (μg/dL) 1.12 ± 0.19 (1.0-2.0) TSH (mU/mL) 2.06 ± 2.13 (0.1-23.0)
Table 3 Correlation of histological fibrosis severity with the variables
Bivariate Spearman’s rank correlation coefficient (95% CI) P valueAge (yr) 0.232 (0.108-0.349) < 0.001 AST (U/L) 0.188 (0.062-0.308) 0.004 ALT (U/L) -0.028 (-0.155 to 0.100) 0.666 PT INR 0.337 (0.219-0.445) < 0.001 PLT (× 103 /μL) -0.326 (-0.435 to -0.207) < 0.001 Hb -0.176 (-0.297 to -0.050) 0.005 WBC -0.053 (-0.179 to 0.075) 0.404 Cr -0.152 (-0.274 to -0.025) 0.02 FT4 -0.167 (-0.288 to -0.040) 0.014 TSH 0.065 (-0.063 to 0.191) 0.341 Bil(T) 0.135 (0.008-0.258) 0.04 AAR 0.341 (0.223-0.449) < 0.001 APRI 0.322 (0.203-0.431) < 0.001 FibroQ 0.444 (0.336-0.541) < 0.001 FIB-4 0.429 (0.319-0.528) < 0.001 CDS 0.185 (0.059-0.305) 0.004 API 0.360 (0.244-0.466) < 0.001 Lok’s model 0.430 (0.320-0.528) < 0.001 Pohl score 0.144 (0.017-0.267) 0.027
Table 4 Correlation between fibrosis score and aspartate aminotransferase-to-platelet ratio index, aspartate aminotransferase/alanine aminotransferase ratio, and FibroQ, FIB-4, cirrhosis discriminant score, age-platelet index, Lok’s model, Pohl score
Metavir fibrosis score F1 F2 F3 F4 Patient number (%) 41 (17.3) 85 (35.9) 98 (41.4) 13 (5.5) AAR 0.566 ± 0.162c e 0.673 ± 0.250 0.749 ± 0.222 0.776 ± 0.175 APRI 1.433 ± 1.040a 1.919 ± 1.904 2.320 ± 1.390 2.508 ± 1.102 FibroQ 1.485 ± 0.855g i 2.532 ± 1.660m 3.563 ± 2.056 3.581 ± 1.812 FIB-4 1.79 ± 1.13g i m 2.79 ± 2.03 3.75 ± 1.97 3.82 ± 1.57 CDS 5.61 ± 1.16 5.69 ± 1.19 6.14 ± 1.12 6.15 ± 1.41 API 3.95 ± 2.06g i m 5.25 ± 2.24 6.40 ± 2.29 6.15 ± 1.63 Lok’s model 0.22 ± 0.12k m o 0.32 ± 0.18 0.43 ± 0.19 0.46 ± 0.18 Pohl score 0 0.01 ± 0.11 0.08 ± 0.28 0.04 ± 0.19
Table 5 Performance of simple fibrosis prediction tests for significant fibrosis (F2, F3 and F4) and extensive fibrosis (F3 and F4)
Metavir fibrosis score vs AUC (F2, F3, F4) (95% CI) AUC (F3, F4) (95% CI) AAR 0.709 (0.626-0.792) 0.675 (0.607-0.743) APRI 0.651 (0.566-0.736) 0.681 (0.613-0.749) FibroQ 0.789 (0.720-0.857) 0.728 (0.662-0.793) FIB-4 0.785 (0.686-0.830) 0.725 (0.659-0.791) CDS 0.580 (0.485-0.674) 0.609 (0.537-0.680) API 0.739 (0.660-0.818) 0.696 (0.628-0.764) Lok’s model 0.768 (0.695-0.840) 0.721 (0.656-0.786) Pohl score 0.523 (0.429-0.617) 0.532 (0.458-0.606)
Table 6 Diagnostic accuracy of simple fibrosis prediction tests for significant and extensive fibrosis
Score Cut-off value (%) Significant fibrosis (F2, F3 and F4) Extensive fibrosis (F3 and F4) Sen Spe PPV NPV Sen Spe PPV NPV FibroQ > 0.6 94.9 96.4 12.2 84.0 41.7 97.3 7.14 48.0 75.0 > 1.2 79.7 85.7 48.8 88.9 41.7 90.1 29.4 52.9 77.1 > 1.4 74.3 80.1 53.7 89.2 36.1 86.5 36.5 54.5 75.4 > 1.6 70.0 77.6 65.9 91.6 38.0 85.6 43.7 57.2 77.5 > 1.8 66.2 74.0 70.7 92.4 36.3 83.8 49.2 59.2 77.5 > 2.0 60.8 69.4 80.5 94.4 35.5 82.0 57.9 63.2 78.5 > 2.6 44.3 51.0 87.8 95.2 27.3 64.9 73.8 68.6 70.5 AAR > 0.4 97.0 95.4 12.2 83.9 35.7 96.4 7.1 47.8 69.2 > 0.6 61.2 67.9 70.7 91.7 31.5 77.5 53.2 59.3 72.8 > 0.8 28.7 31.6 85.4 91.2 20.7 36.9 78.6 60.3 58.6 > 1.0 6.8 8.16 100 100 18.5 10.8 96.8 75.0 55.2 APRI > 0.5 95.8 96.9 9.7 83.7 40.0 99.1 7.1 48.5 90.0 > 1 72.6 75.5 41.5 86.0 26.2 87.4 40.5 56.4 78.5 > 1.5 54.0 56.6 58.5 86.7 22.0 69.4 59.5 60.2 68.8 > 2 39.7 45.4 87.8 94.7 25.2 55.0 73.8 64.9 65.0 CDS > 5 88.6 88.8 12.2 82.9 18.5 92.8 15.1 49.0 70.4 > 6 63.7 66.3 48.8 86.1 23.3 73.9 45.2 54.3 66.3 > 7 29.1 30.6 78.0 87.0 19.0 34.2 75.4 55.1 56.5 > 8 8.9 9.7 95.1 90.5 18.1 12.6 94.4 66.7 55.1 API > 4 75.9 81.6 51.2 88.9 36.8 87.4 34.1 53.9 75.4 > 5 67.1 73.5 63.4 90.6 33.3 82.0 46.0 57.2 74.4 > 6 57.4 63.3 70.7 91.2 28.7 74.8 57.9 61.0 72.3 > 7 39.7 46.4 92.7 96.8 26.6 56.8 75.4 67.0 66.4 Pohl score Positive 3.8 4.59 100 100 18.0 7.2 99.2 88.9 54.8 FIB-4 > 1.45 75.5 81.6 53.7 89.4 37.9 87.4 34.9 54.2 75.9 > 2 62.0 69.4 73.2 92.5 33.3 81.1 54.8 61.2 76.7 > 2.5 53.6 61.2 82.9 94.5 30.9 74.8 65.1 65.4 74.5 > 3 46.0 52.6 85.4 94.5 27.3 66.7 72.2 67.9 71.1 > 3.25 40.9 47.4 90.2 95.9 26.4 61.3 77.0 70.1 69.3 Lok’s model > 0.2 74.7 81.6 58.5 90.4 40.4 88.3 37.3 55.4 78.3 > 0.4 35.0 40.8 92.7 96.4 24.7 51.4 79.4 68.7 64.9 > 0.5 24.1 28.6 97.6 98.2 22.2 37.8 88.1 73.7 61.7